It is uncertain how the drug pricing provisions imposed by the IRA, or results on any related litigation, will impact the broader pharmaceutical industry or our business.
All entries for: Biologic
February 26, 2026
Opko Health Inc
Neutral Outlook
Waltham, MA
501-1,000 employees
The IRA has had and will likely continue to have a significant impact on the pharmaceutical industry.
Disease Area: Endocrinology, Immune Diseases, Infectious Diseases, Oncology
Drug Type: Biologic, Small Molecule
February 26, 2026
BioMarin Pharmaceutical Inc.
Neutral Outlook
San Rafael, CA
1000-5000 employees
Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry.
Disease Area: Cardiology, Chronic Disease, Multiple, Rare Diseases
Drug Type: Biologic, Small Molecule
February 26, 2026
Crinetics Pharmaceuticals Inc.
Neutral Outlook
San Diego, CA
501-1,000 employees
While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run.
Disease Area: Endocrinology, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
February 26, 2026
Pfizer - New York
Neutral Outlook
New York, NY
10,000+ employees
We continue to evaluate the impact of the IRA on our business, operations and financial condition and results as the full effect of the IRA on our business and the pharmaceutical industry remains uncertain.
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
February 26, 2026
Denali Therapeutics Inc
Neutral Outlook
South San Francisco, CA
501-1,000 employees
While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run.
Disease Area: Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule
February 26, 2026
Ironwood Pharmaceuticals, Inc.
Neutral Outlook
Boston, MA
201-500 employees
As another example, the Inflation Reduction Act, or IRA, of 2022, contains various drug pricing and payment provisions. Among other provisions, the IRA imposes a yearly cap ($2,000 in 2025) on out-of-pocket prescription drug prices in Medicare Part D.
Disease Area: Gastrointestinal, Rare Diseases
Drug Type: Biologic, Small Molecule
February 26, 2026
Rocket Pharmaceuticals
Neutral Outlook
Cranbury, NJ
201-500 employees
Implementation of the Inflation Reduction Act has occurred, but the results of its impact on the market for drugs, including our products, remains uncertain.
Disease Area: Cardiology, Immune Diseases, Multiple, Rare Diseases
Drug Type: Biologic
February 26, 2026
Biocryst Pharmaceuticals
Negative Outlook
Durham, NC
501-1,000 employees
The IRA or other government efforts to reduce the price of prescription drugs or to limit the amount that governments pay for healthcare products and services could result in additional pricing pressure and have a significant impact on our business.
Disease Area: Rare Diseases
Drug Type: Biologic, Small Molecule